Bellicum Pharmaceuticals, Inc. is making strides in the biopharmaceutical industry as it focuses on the development of innovative cellular immunotherapies for hematological cancers and solid tumors in both the United States and internationally. The company's clinical product lineup features BPX-601, an autologous GoCAR-T product that is currently in Phase 1/2 clinical trials for treating solid tumors that express the prostate stem cell antigen. In addition, Bellicum is working on BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for treating solid tumors expressing human epidermal growth factor receptor 2 antigen. Their collaborations and license agreements with reputable firms such as Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine further solidify their position as a top industry competitor. Founded in Houston, Texas in 2004, Bellicum Pharmaceuticals, Inc. is pushing the boundaries of cellular-based cancer therapies.
Bellicum Pharmaceuticals Inc's ticker is BLCM
The company's shares trade on the NASDAQ stock exchange
They are based in Houston, Texas
There are 51-200 employees working at Bellicum Pharmaceuticals Inc
It is http://www.bellicum.com/
Bellicum Pharmaceuticals Inc is in the Healthcare sector
Bellicum Pharmaceuticals Inc is in the Biotechnology industry
The following five companies are Bellicum Pharmaceuticals Inc's industry peers: